Is Ageing Finally Defeated? Revolutionary AI Unleashes Potent Drugs to Combat the Biological Clock

by Wall Street Rebel - Michael London | 08/11/2023 12:52 PM
Is Ageing Finally Defeated? Revolutionary AI Unleashes Potent Drugs to Combat the Biological Clock

The field of molecular biology has advanced significantly due to the efforts of researchers who have found a novel collection of chemicals capable of effectively targeting and treating aging cells using a cutting-edge machine-learning approach.


Finding new pharmaceuticals - often known as "drug discovery" - is an expensive and time-consuming process. However, a sort of artificial intelligence known as machine learning can significantly speed up the process and complete the task for a fraction of the cost.

Artificial intelligence (AI) has emerged as a pivotal catalyst for numerous significant advancements over the past year. In recent times, the internet has been captivated by the emergence of super-intelligent chatbots and the rapid generation of art. However, artificial intelligence (AI) has also made significant strides in addressing a major concern for humanity: the process of aging.

A team of researchers from the University of Edinburgh has made a significant breakthrough in the field of drug discovery by employing machine-learning systems. This innovative approach has led to the identification of a range of promising new pharmaceuticals with potential anti-aging properties.

One of the subfields that fall under the umbrella of artificial intelligence (AI) is known as machine learning, and its primary focus is on using data to model how humans acquire knowledge. This strategy emphasizes improving the accuracy of the results by gradually incorporating increasing amounts of data. Throughout human history, the algorithm in question has shown its adaptability in various applications, such as creating robots that can play chess, autonomous vehicles, and tailored television suggestions. However, the goal it is focusing on at the moment is the development of a novel senolytics medicine.

Subscribe 100% Free to Wall Street and receive access to investment tools worth $17,500!

Senolytics are a class of medicinal drugs with the amazing capacity to slow down the aging process while simultaneously reducing the risk of developing age-related illnesses and slowing their progression. Senolytics can perform their job by removing senescent cells in a specific manner. Senescent cells are damaged cells that have lost their ability to proliferate but can still emit pro-inflammatory chemicals.

The research and development of senolytics can be time-consuming and expensive, even though these drugs have great therapeutic promise. In light of this observation, Vanessa Smer-Barreto, a distinguished research fellow at the respected University of Edinburgh linked with the Institute of Genetics and Molecular Medicine, set out to harness the potential of machine learning techniques.

According to Smer-Barreto, the process of obtaining personal biological data can incur large expenditures and require a great amount of time, particularly when it comes to collecting training data. This is especially true when it comes to collecting data for athletes.

Our strategy distinguishes out from others since we make concerted efforts to accomplish our objectives while utilizing a constrained amount of financial resources. In the course of the research, we used training data gleaned from previously published scientific literature to investigate the feasibility of applying machine learning algorithms to speed up operations.

Using a machine learning algorithm, the researcher successfully identified three potential candidates for pharmaceutical compounds of this nature.

To accomplish this task, Smer-Barreto and her colleagues employed a methodology wherein an artificial intelligence (AI) model was provided with a dataset consisting of both senolytic and non-senolytic compounds. The model was trained to effectively discern and differentiate between these two categories through this process. This approach enables the prediction of the senolytic properties of previously unseen molecules by assessing their similarity to pre-fed examples.

Approximately 80 senolytics have been identified; however, only two of them have undergone clinical trials involving human subjects. Although the proportion may appear small at first glance, it is crucial to acknowledge that the journey from drug development to market availability is a lengthy and resource-intensive process, typically spanning a period of 10 to 20 years. Substantial financial investments accompany this arduous timeline.

The research team meticulously reviewed an extensive array of scientific papers, employing a discerning approach to identify and include only 58 compounds in their study. To ensure precision and accuracy, the researchers selectively eliminated any compounds from their analysis that exhibited ambiguous or inconclusive outcomes.

The machine-learning model was provided with a dataset consisting of 4,340 molecules, and within a remarkably short span of five minutes, it generated a comprehensive list of results. The model successfully identified a set of 21 molecules that exhibited high scores and were thus predicted to possess senolytic properties. The absence of a machine-learning model would necessitate a significantly longer duration and substantial financial resources to obtain the outcomes.

Subsequently, a comprehensive evaluation of potential drug candidates was conducted, encompassing their effects on two distinct cellular populations: healthy cells and cells exhibiting signs of aging.

Three of the molecules with the highest scores were able to eliminate senescent cells while selectively protecting the viability of normal cells. This extraordinary ability was proven by three of the 21 compounds. After that, the innovative senolytics were put through additional testing in order to get a more in-depth comprehension of the mechanisms of action that they employ within the human body.

Although the study yielded positive results, it represents merely the initial phase of this ongoing research endeavor. Smer-Baretto elucidates that the subsequent course of action entails establishing a collaborative partnership with clinicians affiliated with our esteemed university. This collaboration aims to conduct rigorous testing of the drugs we have discovered, utilizing samples of resilient human lung tissue provided by clinicians.

In the following experiments, the research team aims to investigate the potential of combating aging within the tissue of impaired organs. According to Smer-Baretto, it is important to note that patients in the earlier stages of treatment may not receive a high dosage of medication. Preliminary testing of these drugs is conducted on tissue models to ensure safety and efficacy. Additionally, the administration of drugs can be localized or implemented through micro-dosing techniques.

According to Smer-Baretto, it is crucial to consider the potential for harm outweighing the benefits when administering or conducting experiments with any pharmaceutical substance.

The pharmaceutical compounds undergo a rigorous series of stages before being approved for market release. Furthermore, before reaching the market, these compounds are subjected to an extensive battery of safety evaluations and tests.

This data analysis method was initially employed in studying drugs associated with aging. However, no inherent limitations prevent using this artificial intelligence in various other domains.

Subscribe 100% Free to Wall Street and receive access to investment tools worth $17,500!


                       The Future of Artificial Intelligence - Shaping our AI Futures-Terrific Educational Lecture

Latest News

Stay Up to Date With The Latest
News & Updates

Join Our Newsletter


Rebel Yell Morning Market Report
Market Alerts
Offers from us
Offers from our trusted partners

Follow Us

Connect with us on social media

Facebook Twitter